

LIST OF CONTENTS

Chapter	Page
I INTRODUCTION 1	1
Statement of purpose.....	1
Objectives of the study.....	2
Hypothesis of the study.....	2
Scope of research	2
Expected outcomes	3
II LITERATURE REVIEWS	4
Antiretroviral therapy.....	4
The human leukocyte antigen (HLA) system	9
HLA Class I	9
HLA Class II.....	9
Role of genetics and HLA genotypes in ADRs	10
The hapten concept model	11
The p-i model (pharmacologic interaction)	11
The altered repertoire model.....	12
III RESEARCH METHODOLOGY	15
Identification of studies.....	15
Appraisal and selection of studies	16
Data extraction and quality assessment	17
Data analyses	17
Systematic review	17
Meta-analysis	17

LIST OF CONTENTS (CONT.)

Chapter	Page
IV RESULTS AND DISCUSSIONS	19
Section I: Abacavir	19
Section II: Nevirapine	32
Section III: Stavudine	49
V CONCLUSIONS	58
Section I: Abacavir	58
Section II: Nevirapine	58
Section III: Stavudine	58
REFERENCE	60
APPENDIXES	73
BIOGRAPHY	102

LIST OF TABLES

Table		Page
1	Criteria for ART Initiation in specific populations [38]	6
2	Regimens for initiating treatment of HIV infection.....	6
3	Search terms used for identify relevant studies	16
4	Characteristics of abacavir studies meeting the selection criteria.....	22
5	Patient demographic information in abacavir included studies for the meta-analysis.....	23
6	Reported odds ratio of the abacavir included studies and summary odds ratio categorized by ethnicity	31
7	Characteristics of nevirapine studies which were met with the selection criteria	35
8	Reported odds ratio of the nevirapine included studies categorized by HLA genotypes and ADRs	45
9	Characteristics of stavudine studies meeting the selection criteria.....	52
10	Summary patient demographic information of stavudine included studies for the meta-analysis	53
11	Reported odds ratio of the stavudine included studies and summary odds ratio.....	55

LIST OF FIGURES

Figure	Page
1 Timeline of antiretroviral	5
2 Structure of abacavir	7
3 Structure of nevirapine.....	7
4 Structure of stavudine	8
5 HLA class I and HLA class II molecule	10
6 Models of the interaction between drug and TCR	12
7 Models for generation of immunogenic HLA-B*5701 and abacavir peptide complexes.....	13
8 The 3D conformation of SI9 is very similar between abacavir-HLA complex and HLA-B*5801	14
9 A step approaches in our systematic review and meta-analysis	15
10 A flow diagram of our systematic searching procedure for the studies related to the association of abacavir included hypersensitivity reactions and HLA-B*5701	20
11 Random effects meta-analysis of abacavir-induced hypersensitivity among HLA-B*5701 positive.....	25
12 Random effects meta-analysis of abacavir-induced hypersensitivity among HLA-B*5701 positive according to ethnicity	26
13 Random effects meta-analysis of abacavir-induced hypersensitivity among HLA-B*5701 positive whites, according to the diagnostic method of detecting hypersensitivity	27
14 A funnel plot of the abacavir studies	28
15 A flow diagram of our systematic searching procedure for the studies related to the association of nevirapine included adverse drug reactions and HLA genotypes	33
16 Random effects meta-analysis of nevirapine-induced skin reaction among HLA-Cw*04 positive.....	42

LIST OF FIGURES (CONT.)

Figure	Page
17 Random effects meta-analysis of nevirapine-induced HSR among HLA-Cw*08 positive.....	43
18 A flow diagram of our systematic searching procedure for the studies related to the association of stavudine-induced lipodystrophy and HLA-B*4001	50
19 Random-effects meta-analyses of stavudine-induced lipodystrophy among HLA-B*4001 positive.....	54

ABBREVIATIONS

ABC	=	Abacavir
ADR	=	Adverse drug reaction
HLA	=	Human Leukocyte Antigen
HSR	=	Hypersensitivity reaction
D4T	=	Stavudine
MHC	=	Major histocompatibility complex
ND	=	Not determined
NR	=	Not reported
NOS	=	Newcastle-Ottawa scale
NVP	=	Nevirapine
OR	=	Odds ratios
RCT	=	Randomized control studies
ROB	=	Risk of bias
SJS	=	Stevens-Johnson syndrome
TCR	=	T cell receptor
TEN	=	Toxic epidermal necrolysis